Claims
- 1. A free flowing or granular powder pharmaceutical formulation consisting of amoxycillin hydrate, a .beta.-lactamase inhibitor, and an effervescent couple, the couple comprising an acid component and an alkaline component, which generates carbon dioxide on contact with water, in which the alkaline component of the couple is present in excess of the stoichiometric equivalent of the acid component and which is in a sufficient amount to both neutralize the acid component and to solubilize the amoxycillin hydrate; a sweetener, and a flavoring agent.
- 2. A pharmaceutical formulation according to claim 1 in which the amoxycillin hydrate is amoxycillin trihydrate.
- 3. A pharmaceutical formulation according to claim 1 in which the proportion of amoxycillin hydrate is 10-30% by weight.
- 4. A pharmaceutical formulation according to claim 1 which when made up into aqueous solution has a pH of not less than 8.
- 5. A pharmaceutical formulation according to claim 1 which contains 50-75 weight % of alkaline component.
- 6. A pharmaceutical formulation according to claim 1 in which the alkaline component is a 3-1.5: 1 by weight mixture of sodium glycine carbonate: potassium bicarbonate.
- 7. A pharmaceutical formulation according to claim 1 which contains 5-20 weight % of the acid component.
- 8. A pharmaceutical formulation according to claim 1 containing a molar ratio of sodium glycine carbonate: amoxycillin: potassium bicarbonate: citric acid in the range 4-10: 1-3: 5-10: 1.
- 9. A pharmaceutical formulation according to claim 1 in which the amoxycillin hydrate is in combination with the .beta.-lactamase inhibitor clavulanic acid or a salt thereof.
- 10. A pharmaceutical formulation according to claim 23 in which the .beta.-lactamase inhibitor is clavulanic acid or potassium clavulanate and is present in a weight ratio of amoxicillin hydrate to inhibitor of 12:1 to 1:1.
- 11. A pharmaceutical formulation according to claim 23 in which the amoxycillin hydrate is amoxycillin trihydrate.
- 12. A pharmaceutical formulation according to claim 1 in which the alkaline component is a mixture of sodium or potassium hydrogen carbonate or sodium or potassium glycine carbonate.
- 13. A pharmaceutical formulation according to claim 1 in which the acid component of the effervescent couple is selected from the group consisting of citric acid, tartaric acid, malic acid and mixtures thereof; and the alkaline component of the effervescent couple is selected from the group consisting of sodium bicarbonate, sodium glycine carbonate, sodium carbonate, corresponding potassium salts and mixtures thereof.
- 14. A free flowing or granular powder pharmaceutical formulation provided as a unit dose, and consisting of amoxycillin hydrate, a .beta.-lactamase inhibitor, and an effervescent couple, the couple comprising an acid component and an alkaline component, which generates carbon dioxide on contact with water, in which the alkaline component of the couple is present in excess of the stoichiometric equivalent of the acid component and which is in a sufficient amount to both neutralize the acid component and to solubilize the amoxycillin hydrate; a sweetener, and a flavoring agent.
- 15. The pharmaceutical formulation according to claim 14 wherein the amoxycillin hydrate is amoxycillin trihydrate.
- 16. The pharmaceutical formulation according claim 15 in which the proportion of amoxycillin hydrate is 10-30% by weight.
- 17. The pharmaceutical formulation according to claim 14 in which the acid component of the effervescent couple is selected from the group consisting of citric acid, tartaric acid and malic acid and mixtures thereof, and the alkaline component of the effervescent couple is selected from the group consisting of sodium bicarbonate, sodium glycine carbonate and sodium carbonate, the corresponding potassium salts, and mixtures thereof.
- 18. The pharmaceutical formulation according to claim 14 which when made up into aqueous solution has a pH of not less than 8.
- 19. The pharmaceutical formulation according to claim 14 which contains 50 to 75 weight % of alkaline component.
- 20. The pharmaceutical formulation according to claim 19 in which the alkaline component is a 3-1.5: 1 by weight mixture of sodium glycine carbonate: potassium bicarbonate.
- 21. The pharmaceutical formulation according to claim 14 which contains 5 to 20 weight % of the acid component.
- 22. The pharmaceutical formulation according to claim 20 containing a molar ratio of sodium glycine carbonate: amoxycillin : potassium bicarbonate: citric acid in the range 4 to 10:1 to 3:5 to 10:1.
- 23. The pharmaceutical formulation according to claim 14 wherein the .beta.-lactamase inhibitor is clavulanic acid or a salt thereof.
- 24. A pharmaceutical formulation according to claim 14 containing a unit dose of amoxycillin between 125 and 3000 mg.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9007945 |
Apr 1990 |
GBX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/328,313 filed Oct. 24, 1994 now U.S. Pat. No. 5,814,337 which is a continuation of application Ser. No. 07/934,757 filed Oct. 7, 1992 now abandoned.
US Referenced Citations (9)
Foreign Referenced Citations (10)
Number |
Date |
Country |
710859 |
Aug 1968 |
BEX |
0080862 |
Jun 1983 |
EPX |
0 281 200 |
Sep 1988 |
EPX |
27 50 207 |
Nov 1978 |
DEX |
79019 |
Jun 1982 |
ROX |
1178294 |
|
GBX |
1221038 |
Feb 1971 |
GBX |
1276839 |
Jun 1972 |
GBX |
1300998 |
Dec 1972 |
GBX |
8809173 |
Dec 1988 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Tsuji, et a., Journal of Pharmaceutical Sciences, vol. 67 (8) Aug. 1978, pp. 1059-1066. |
Eugene L. Parrott, "Pharmaceutical Technology", p. 64-65. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
328313 |
Oct 1994 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
934757 |
Oct 1992 |
|